• Photocure ASA, of Oslo, Norway, reported final results from its Phase IIb study of Cevira in patients with human papillomavirus (HPV)-related disease of the cervix, showing that the drug-delivery device demonstrated significant and sustained efficacy in the eradication of oncogenic HPV infections and precancerous lesions in CIN2 patients.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter